21 Oct 2022 07:00
REACH: non-regulatory announcement
21 October 2022
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Notice of Investor / Analyst Event
Advanced Oncotherapy (AIM: AVO), the developer of LIGHT, the next generation proton therapy system for cancer treatment, announces that it will hold an investor and analyst event at its assembly site in Daresbury, Cheshire, between 13:00 - 16:30 GMT on Tuesday, 8 November 2022.
At the event, which follows the Company's announcement on 27 September 2022 that its LIGHT accelerator is fully operational and has achieved a 230 megaelectron volts ("MeV") beam, the Company's executive management team will present the recent operational progress achieved on the LIGHT machine, the commissioning and certification process, current market dynamics and how the Company's business model and commercial strategy are expected to lead to the successful rollout of LIGHT.
To register your interest in attending this event, please contact ir@avo-adam.com. The event will be held in person and will also include a tour of the site's technical area including the first operational LIGHT system. Due to health & safety restrictions in the technical area of the LIGHT system the total number of visitors is limited and therefore any application to attend the event will be subsequently confirmed based on the total number of registrations received.
The presentation will be available on the Company's website on the day of the event.
For more information on LIGHT, please see this video explaining the technology.
The full agenda for the event is as follows:
Presentation | Time (GMT) |
Arrival at Daresbury | 12:45 |
Presentation by the Company's management including: | 13:00 - 14:00 |
Nicolas Serandour, Chief Executive Officer | |
Prof. Steve Myers. Executive Chairman ADAM S.A. | |
Ed Lee, Chief Operating Officer | |
Moataz Karmalawy, Chief Commercial Officer | |
Jonathan Farr, Chief Clinical Officer | |
Tour of the technical area and LIGHT system | 14:00 - 15:30 |
Q&A | 15:30 - 16:30 |
- ENDS -
Advanced Oncotherapy plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO |
|
| |
Allenby Capital Limited (Nomad and Joint Broker) | |
Nick Athanas / Piers Shimwell (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking) | Tel: +44 (0) 20 3328 5656 |
SI Capital Ltd (Joint Broker) |
|
Nick Emerson | Tel: +44 (0) 1483 413 500 |
Jon Levinson | Tel: +44 (0) 20 3871 4066 |
| |
FTI Consulting (Financial PR & IR) | advancedoncotherapy@fticonsulting.com |
Simon Conway / Rob Winder | Tel: +44 (0) 20 3727 1000 |
Notes to Editors
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.